Therapy and prognosis of adult Focal Segmental Glomerulosclerosis

Objective: To analyze and assess the treatment approaches for focal segmental glomerulosclerosis (FSGS) in adults. Methods: We searched seven databases on literatures between 1993 and 2010 related to the therapy and prognosis of focal segmental glomerulosclerosis in adults. The literature research showed that all FSGS therapy aimed to reduce urine protein an d protect renal function. According to the literature, FSGS patients usually should receive both immune and non-immune therapy. The immune therapy includes controlling blood pressure, blood fat and weight, while the non-immune therapy includes using hormonotherapy on mild or first-treated patients or taking hormone, immunosuppressant (cyclophosphamide, azathioprine and mycophenolate mofetil), Calcineurin inhibitors (cyclosporine and FK506), Rityximab and plasma exchange for seriously ill pati ents or patients who experience recurrence or depend on or resist hormone. Results: As the etiology of FSGS in adults is diverse and complicated, a variety of therapeutic approaches have been developed and tested on small groups of FSGS paitents. Each individual treatment has its own advantages and disadvantages. However, the remission rate for neither treatment is satisfactory. A better treatment should be developed and assessed with evidence-based largescale and multi-center medical trials . Conclusion: The current therapy approaches for adults FSGS have certain treatment effect. However, more work is required in developing a better new approach.